Kevin Chang

Kevin Chang is an experienced pharmaceutical professional currently serving as Director at BlossomHill Therapeutics, Inc. and Associate Director at Bristol Myers Squibb since August 2022. Previously held the position of Associate Director at Turning Point Therapeutics from April 2019 to August 2022, focusing on the development of pharmaceutical dosage forms and manufacturing processes for small molecule-based drugs. Kevin's career includes significant roles as Principal Scientist at Amgen Inc. from 2006 to 2019, where expertise in formulation and process development for various oral and sterile products resulted in successful regulatory filings. Prior experience as Principal Scientist at Pfizer Inc. involved formulation development for pipeline drug candidates and contributing to IND filings. Early career experience includes research at International Paper and a postdoctoral fellowship at the University of Michigan. Educational qualifications include a PhD in Chemical Engineering from the University of Michigan and both an MS and BS in Chemical Engineering from National Taiwan University.